BusinessCURE Pharmaceutical Attracts Strategic Investment to Speed Its Cannabinoid Drug Delivery ProductionBy Nasdaq OMXMay 1, 2018, 12:57 PM UTC
BusinessCURE Pharmaceutical Secures Two Patents for the Extraction and Purification of Bioactive Cannabinoid MoleculesBy Nasdaq OMXApr 4, 2018, 12:57 PM UTC
BusinessCURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of YearBy Nasdaq OMXApr 3, 2018, 12:57 PM UTC
BusinessUPDATED – Hawaii Cannabis Science Dinner & Dialogue Panel to Discuss Company’s Research on the Endocannabinoid System for Breakthrough TherapiesBy Nasdaq OMXMar 24, 2018, 12:43 AM UTC
BusinessCURE Pharmaceutical to Participate in Hawaiian Cannabis Science Dinner & Dialogue Panel to Discuss Company’s Research on the Endocannabinoid System for Breakthrough TherapiesBy Nasdaq OMXMar 23, 2018, 3:00 PM UTC
BusinessCURE Pharmaceutical Announces Closing of $1 Million Bridge Financing and Prepares to Uplist to NASDAQBy Nasdaq OMXMar 23, 2018, 1:00 PM UTC
BusinessBiopharmaceutical Veteran Joins CURE Pharmaceutical to Lead ManufacturingBy Nasdaq OMXMar 14, 2018, 1:01 PM UTC
BusinessCURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to UplistingBy Nasdaq OMXFeb 21, 2018, 11:00 AM UTC
